Bemiparin (trade names Ivor and Zibor, among others) is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).[1]
Clinical data | |
---|---|
Trade names | Badyket, Ivor, Hibor, Zibor, others |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Subcutaneous injection (except for haemodialysis) |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | 96% (estimated) |
Elimination half-life | 5–6 hours |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
Chemical and physical data | |
Molar mass | 3600 g/mol (average) |
(what is this?) (verify) |
Bemiparin is used for the prevention of thromboembolism after surgery, and to prevent blood clotting in the extracorporeal circuit in haemodialysis.[2]
The medication is contraindicated in patients with a history of heparin-induced thrombocytopenia with or without disseminated intravascular coagulation; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or pancreas impairment; and acute or subacute bacterial endocarditis.[2]
No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, aspirin and other NSAIDs, antiplatelet drugs, and corticosteroids.[2]
Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 g/mol on average.[3] (Enoxaparin has 4500 g/mol.) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.[4]